Tetanus and diphtheria toxoids adsorbed
Trade name: Decavac
Vaccineapproved
Approved
Mar 7, 1955
Tetanus vaccine, also known as tetanus toxoid (TT), is a toxoid vaccine used to prevent tetanus. During childhood, five doses are recommended, with a sixth given during adolescence. — Wikipedia
Clinical trial activity
40 trials · 44 clinical orgs · 2 marketing orgs
Phase 1
14
Phase 2
17
Phase 3
11
Phase 4
8
Earliest trial started Apr 1, 1991 (NCT00004799)
Timeline
1950s
- Mar 7, 1955
Earliest FDA Approval
1970s
- Jul 27, 1970
MassBiologics — First NDA Organization
- Jul 27, 1970
MassBiologics — NDA Secondary Org
- Jul 27, 1970
MassBiologics — NDA Organization
1990s
- Jan 1, 1991
Earliest Phase 3 Sponsor(trial)
- Dec 9, 1999
Sanofi-Aventis — NDA Secondary Org
Indications
Approved for
Studied for
- Adult · Phase 4
- Air Pollution · Phase 4
- Antibodies · Phase 4
- Bacterial Infections · Phase 3
- Brain Neoplasms · Phase 1
- Breast Neoplasms · Phase 2
- Colonic Neoplasms · Phase 2
- COVID-19 · Phase 3
- Diarrhea · Phase 3
- Diffuse Intrinsic Pontine Glioma · Phase 2
- Diphtheria · Phase 4
- Diphtheria-Tetanus-acellular Pertussis Vaccines · Phase 3
- Diphtheria-Tetanus-Pertussis Vaccine · Phase 3
- Environmental Exposure · Phase 4
- Glioblastoma · Phase 1
- Glioma · Phase 2
- Gonorrhea · Phase 2
- Healthy Volunteers · Phase 3
- Hepatitis C · Phase 1
- HIV · Phase 4
- HIV Infections · Phase 1
- Immunity · Phase 4
- Infections · Phase 2
- Inflammation · Phase 4
- Medulloblastoma · Phase 2
- Melanoma · Phase 1
- Multiple Sclerosis · Phase 2
- Pertussis Vaccine · Phase 3
- Pneumococcal Infections · Phase 1
- Primary Immunodeficiency Diseases · Phase 4
- Substance-Related Disorders · Early Phase 1
- Tetanus · Phase 4
- Urinary Bladder Neoplasms · Phase 2
- Vaccination · Phase 4
- Vaccines · Phase 4
- Whooping Cough · Phase 4
Mechanism of action
- Corynebacterium diphtheriaeImmunity, active
Corynebacterium diphtheriae immunity, active
- Clostridium tetaniImmunity, active
Clostridium tetani immunity, active
Approval history
- approvedMar 7, 1955
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaTetanus vaccine ↗
- WikipediaDPT vaccine ↗
Also known as
- decavac
- diphtheria and tetanus toxoids adsorbed
- diphtheria and tetanus vaccine
- diphtheria-tetanus toxoids adsorbed
- diphtheria/tetanus vaccine
- gc1107
- td-pur
- td-rix
- td vaccine
- tedivax-adult
- tetanus and diphtheria vaccine
- tetanus and diptheria toxoids adsorbed
- tetanus-diphtheria toxoid
- tetanus-diphtheria vaccine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06514898 | Phase 1 | Dec 31, 2024 | Georgetown University, University of Florida |
| NCT06588530 | Phase 4 | Sep 30, 2024 | Rutgers University |
| NCT06254326 | Phase 1 | Sep 19, 2024 | University of Florida |
| NCT06184542 | Phase 1 | Dec 23, 2023 | Chinese Academy of Medical Sciences, Government of China |
| NCT05415267 | Phase 3 | Jan 8, 2023 | Medical Research Future Fund (MRFF), University of New South Wales |
| NCT05294588 | Phase 2 | Apr 18, 2022 | National Institute of Allergy and Infectious Diseases (NIAID), University of North Carolina at Chapel Hill |
| NCT05096481 | Phase 2 | Mar 31, 2022 | Duke University, Ohio State University |
| NCT05077137 | Phase 1 | Sep 7, 2021 | Duke University |
| NCT03396575 | Phase 1 | May 17, 2018 | University of Florida |
| NCT03334305 | Phase 1 | May 16, 2018 | National Cancer Institute (NCI), National Institutes of Health (NIH), National Pediatric Cancer Foundation, University of Florida, University of South Florida |
| NCT03063736 | Early Phase 1 (Phase 1) | Jun 1, 2017 | Baylor University |
| NCT02864368 | Phase 1 | Dec 1, 2016 | Annias Immunotherapeutics, Inc., Duke University, National Cancer Institute (NCI), National Institutes of Health (NIH) |
| NCT02946190 | Phase 2 | Oct 27, 2016 | BioNet-Asia Co., Ltd., University of Geneva |
| NCT04618939 | Phase 3 | Oct 20, 2016 | Boryung Pharmaceutical Company, Catholic University of Korea |
| NCT02673255 | Phase 1 | Aug 1, 2016 | Axio Research Corporation, Grifols, Hammond Clinical Trial Consulting, LLC, RMD Insight, LLC |
| NCT02193347 | Phase 1 | Dec 1, 2015 | Duke University |
| NCT02097849 | Phase 2 | Feb 28, 2015 | Biogen |
| NCT02361866 | Phase 3 | May 1, 2014 | Catholic University of Korea, Green Cross Corporation |
| NCT01993173 | Phase 3 | Nov 1, 2013 | Sanofi |
| NCT01439165 | Phase 4 | Nov 1, 2011 | Sanofi |
Showing 20 of 40 trials
Page 1 / 2
Organizations
Research & Development (44)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 7 | 6 | 4 | 1991 |
| Duke University | Academic/Hospital | 4 | 3 | 2 | 2015 |
| National Institutes of Health (NIH) | Government | 4 | 0 | 2 | 2000 |
| Sanofi | For profit | 4 | 4 | 2 | 2004 |
| University of Florida | Academic/Hospital | 4 | 4 | 1 | 2018 |
| Catholic University of Korea | Academic/Hospital | 3 | 0 | 1 | 2011 |
| National Cancer Institute (NCI) | Government | 3 | 1 | 2 | 2011 |
| GlaxoSmithKline | For profit | 2 | 2 | 1 | 1997 |
| Green Cross Corporation | For profit | 2 | 2 | 1 | 2011 |
| Grifols | For profit | 2 | 2 | 2 | 2007 |
| Intercell | For profit | 2 | 2 | 2 | 2009 |
| AIDS Clinical Trials Group | Academic/Hospital | 1 | 0 | 1 | 2007 |
| Annias Immunotherapeutics, Inc. | For profit | 1 | 0 | 1 | 2016 |
| Axio Research Corporation | For profit | 1 | 0 | 1 | 2016 |
| Baylor University | Academic/Hospital | 1 | 1 | 1 | 2017 |
| Biogen | For profit | 1 | 1 | 1 | 2015 |
| BioNet-Asia Co., Ltd. | For profit | 1 | 0 | 1 | 2016 |
| Boryung Pharmaceutical Company | For profit | 1 | 1 | 1 | 2016 |
| Case Western Reserve University | Academic/Hospital | 1 | 0 | 1 | 2007 |
| Centers for Disease Control and Prevention (CDC) | Government | 1 | 1 | 1 | 2004 |
44 organizations
Page 1 / 3
Marketing (3)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| MassBiologics | Academic/Hospital | NDA2 | Jul 27, 1970 |
| MassBiologics | Academic/Hospital | NDA | Jul 27, 1970 |
| Sanofi-Aventis | For profit | NDA2 | Dec 9, 1999 |